Trial Profile
A Pilot Study of 64-Cu Labeled Brain PET/MRI for MM-302, a Novel HER2 Targeting Agent, in Advanced HER2+ Cancer With Brain Metastases
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase 0
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Gancotamab (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- 02 May 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 19 Apr 2016 New trial record